O
TBPH icon

OppenheimerFunds’s Theravance Biopharma TBPH Stock Holding History

OppenheimerFunds’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-650,190
Closed -$14.8M – 1756
2016
Q2 		$14.8M Sell
650,190
-450,655
-41% -$9.73M 0.02% 644
2016
Q1 		$20.7M Sell
1,100,845
-2,640
-0.2% -$43.2K 0.03% 553
2015
Q4 		$18.1M Buy
1,103,485
+12,120
+1% +$192K 0.02% 606
2015
Q3 		$12M Sell
1,091,365
-5,540
-0.5% -$70.5K 0.02% 683
2015
Q2 		$14.3M Buy
1,096,905
+7,500
+0.7% +$116K 0.02% 674
2015
Q1 		$18.9M Buy
1,089,405
+3,230
+0.3% +$59.2K 0.02% 610
2014
Q4 		$16.2M Buy
1,086,175
+430
+0% +$7.49K 0.02% 637
2014
Q3 		$25M Buy
1,085,745
+126
+0% +$3.66K 0.03% 513
2014
Q2 		$34.6M Buy
+1,085,619
New +$32.7M 0.04% 439

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds's TBPH Position: Q3 2016 in Review

OppenheimerFunds sold out of Theravance Biopharma (TBPH) in Q3 2016, closing a stake of 650,190 shares — an estimated $14.8M sold.

OppenheimerFunds first reported a position in TBPH in Q2 2014 and held it in 9 quarters. The position peaked at $34.6M in Q2 2014. 100 funds tracked by Wall St. Rank hold TBPH as of Q3 2016.

  • OppenheimerFunds reported no remaining Theravance Biopharma position as of Q3 2016 after selling out during the quarter.
  • OppenheimerFunds sold 650,190 Theravance Biopharma shares in Q3 2016, an estimated $14.8M.
  • OppenheimerFunds first reported a position in Theravance Biopharma in Q2 2014 and held it in 9 quarters.
  • OppenheimerFunds's Theravance Biopharma position peaked at $34.6M in Q2 2014.
  • 100 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2016.

Based on OppenheimerFunds's 13F filing for Q3 2016, filed 14 Nov 2016.